PRESSOR AND SUBPRESSOR ANGIOTENSIN-II ADMINISTRATION - 2 EXPERIMENTAL-MODELS OF HYPERTENSION

被引:63
|
作者
SIMON, G
ABRAHAM, G
CSEREP, G
机构
[1] Department of Medicine, VA Medical Center, University of Minnesota, Minneapolis, MN
关键词
HIGH-RENIN HYPERTENSION; RENOVASCULAR HYPERTENSION; PLASMA ANGIOTENSIN II; REGIONAL HEMODYNAMICS; TROPHIC EFFECTS; STRUCTURAL VASCULAR CHANGES;
D O I
10.1016/0895-7061(95)00047-S
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Administered dose is an important determinant of the type of hypertension produced by angiotensin II. With chronic administration of presser doses, there is salt and water retention and expansion of extracellular fluid volume, and the pressure-natriuresis curve is shifted to higher pressures. Important compensatory mechanisms, including resetting of baroreceptors, de novo synthesis of vasodilator prostaglandins, and atrial natriuretic factor release, are triggered by the acute rise of blood pressure. Histologic evidence for vascular injury confounds the interpretation of findings. When angiotensin II is administered in initially subpressor doses, the rise of blood pressure is gradual, there are no detectable changes in salt and water balance, and compensatory mechanisms do not seem to be activated. Autopotentiation of presser and vasoconstrictor responses by angiotensin II is the characteristic feature of the early stages of hypertension induced by small doses of angiotensin II. Trophic stimulation of vascular tissue, in particular restructuring of extracellular matrix, precedes and may, therefore, be the mechanism responsible for the hemodynamic changes. The presser and subpressor models of angiotensin II-induced hypertension draw attention to the relative importance of renal and extrarenal mechanisms in the pathogenesis of hypertension. The long-term administration of initially subpressor doses of angiotensin II mimics the development of human hypertension to a greater extent than does the administration of presser doses.
引用
收藏
页码:645 / 650
页数:6
相关论文
共 50 条
  • [1] AUTOPOTENTIATION OF PRESSOR-RESPONSES BY SUBPRESSOR ANGIOTENSIN-II IN RATS
    ABRAHAM, G
    SIMON, G
    HYPERTENSION, 1992, 20 (03) : 434 - 434
  • [2] AUTOPOTENTIATION OF PRESSOR-RESPONSES BY SUBPRESSOR ANGIOTENSIN-II IN RATS
    ABRAHAM, G
    SIMON, G
    FASEB JOURNAL, 1991, 5 (06): : A1484 - A1484
  • [3] ROLE OF PRESSOR ACTION OF ANGIOTENSIN-II EXPERIMENTAL HYPERTENSION
    PALS, DT
    MASUCCI, FD
    DENNING, GS
    SIPOS, F
    FESSLER, DC
    CIRCULATION RESEARCH, 1971, 29 (06) : 673 - &
  • [4] DEVELOPMENT OF STRUCTURAL VASCULAR CHANGES WITH SUBPRESSOR ANGIOTENSIN-II ADMINISTRATION IN RATS
    SIMON, G
    CSEREP, G
    LIMAS, C
    AMERICAN JOURNAL OF HYPERTENSION, 1995, 8 (01) : 67 - 73
  • [5] HEMODYNAMICS AND CARDIAC MORPHOLOGICAL EFFECTS OF PRESSOR AND SUBPRESSOR DOSES OF ANGIOTENSIN-II (A-II) IN FEMALE RATS
    REAVES, PY
    HOLDER, MS
    MOORE, J
    GERDES, AM
    FASEB JOURNAL, 1993, 7 (04): : A751 - A751
  • [6] EXPERIMENTAL ANGIOTENSIN-II HYPERTENSION
    YOUNG, DB
    MURRAY, RH
    BENGIS, RG
    MARKOV, AK
    AMERICAN JOURNAL OF PHYSIOLOGY, 1980, 239 (03): : H391 - H398
  • [7] AUTOPOTENTIATION OF PRESSER RESPONSES BY SUBPRESSOR ANGIOTENSIN-II IN RATS
    ABRAHAM, G
    SIMON, G
    AMERICAN JOURNAL OF HYPERTENSION, 1994, 7 (03) : 269 - 275
  • [8] PRESSOR SENSITIVITY TO ANGIOTENSIN-I AND ANGIOTENSIN-II DURING THE DEVELOPMENT OF EXPERIMENTAL RENAL-HYPERTENSION IN THE RAT
    DOYLE, AE
    HARRAP, SB
    TORRESI, J
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1986, 13 (07) : 563 - 568
  • [9] Effects of angiotensin-II infusion at pressor and subpressor doses on endothelin-1 plasma levels in healthy men
    Jilma, B
    Krejcy, K
    Dirnberger, E
    Eichler, HG
    Kapiotis, S
    Dorner, GT
    Wagner, OF
    LIFE SCIENCES, 1997, 60 (21) : 1859 - 1866
  • [10] TIME-COURSE OF LOSARTAN BLOCKADE OF ANGIOTENSIN-II HYPERTENSION VERSUS BLOCKADE OF ANGIOTENSIN-II FAST PRESSOR EFFECTS
    GORBEAOPPLIGER, VJ
    MELARAGNO, MG
    POTTER, GS
    PETIT, RL
    FINK, GD
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1994, 271 (02): : 804 - 810